Competing interests
S.J.N. received grant and/or research support from AstraZeneca, NewAmsterdam Pharma, Amgen, Anthera, Cyclarity, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience; and was a consultant for Abcentra, AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Daiichi Sankyo, Silence Therapeutics, CSL Seqirus and Vaxxinity. A.J.N. has received research support from AstraZeneca, Amgen, Eli Lilly and Novartis; and is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, CSL Seqirus, Eli Lilly, GSK, Novartis, Novo Nordisk, Sanofi Pasteur and Vaxxinity. C.M.B. has received grants or research support from Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Merck, NewAmsterdam Pharma, Novartis, Novo Nordisk, Roche Diagnostic, NIH, AHA and ADA; and is a consultant for 89Bio, Abbott Diagnostics, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Illumina, Ionis, Eli Lilly, Merck, NewAmsterdam Pharma, Novartis, Novo Nordisk and Roche Diagnostic. K.K.R. reports research grants from Amgen, Amarin, Sanofi, Daiichi Sankyo and Ultragenyx to Imperial College London; consultancy to Novartis, Daiichi Sankyo, Kowa, Esperion, Novo Nordisk, MSD, Eli Lilly, Silence Therapeutics, AZ, New Amsterdam Pharma, Bayer, Beren Therapeutics, Cleerly, EmendoBio, Scribe, NodThera, CRISPR, Vaxxinity and Sanofi; fees for lectures from Novartis, BI, AZ, Novo Nordisk, Viatris, Amarin, Sanofi, Amgen, Esperion, Daiichi Sankyo, Dr Reddy’s, Mankind and Macleods Pharma for symposia at international meetings; and holding stock options from NewAmsterdam Pharma, Scribe Therapeutics and Pemi31. A.M.N. has received research support to her institution from Amgen and Esperion; and personal fees for consulting from Amgen, Arrowhead, AstraZeneca, Bayer, Eli Lilly, Esperion, Janssen, Merck, NewAmsterdam, Novartis, Novo Nordisk, Pfizer, Roche and Silence Therapeutics. S.E.N. has received research funding to perform clinical trials from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, Esperion Therapeutics, Medtronic, MyoKardia, NewAmsterdam Pharma, Novartis, Pfizer and Silence Therapeutics. A.C.G. has received research support to her institution from Amgen, Arrowhead, Esperion, Ionis, NewAmsterdam Pharma, Novartis, 89Bio Inc. and Sanofi; and personal fees for consulting from Ionis, NewAmsterdam Pharma, Regeneron and Eli Lilly. L.R.B. reports receiving research grants or consulting fees from Amgen, Sanofi, Novartis, HLS Therapeutics, Ionis and NewAmsterdam Pharma. B.A.F. has received research grants and consulting fees from Amgen, AstraZeneca, CiVi Biopharma, Daiichi Sankyo, DalCor, Eli Lilly, Esperion, Ionis Pharmaceuticals, Krka Pharmaceuticals, Merck, Mylan, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, The Medicines Company and Viatris. U.L. has received fees for consulting or lectures from Amgen, Boehringer, Daiichi Sankyo, NewAmsterdam Pharma, Novartis, Sanofi; Leipzig University received research funding from Amgen, Daiichi Sankyo, Novartis and Sanofi. M.B. has received grant(s) and/or research support from Amgen, Daiichi Sankyo, Mylan/Viatris and Sanofi; and has served as a consultant and/or received speaker fees from Adamed, Amgen, Exceed Pharma, Daiichi Sankyo, Esperion, Kogen, KRKA, Lilly, MSD, Mylan/Viatris, NewAmsterdam Pharma, Novartis, Novo Nordisk, Polpharma, Sanofi, Teva and Zentiva. R.M. reports institutional research payments from Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, MediaSphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global BioAccess Fund Management and Sanofi US Services, Inc.; has received personal fees from Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global and Novo Nordisk; and has equity in Elixir Medical, Stel and ControlRad (spouse). A.L.C. has received honoraria, lecture fees or research grants from Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, Novo Nordisk, Regeneron, Sanofi, Ultragenyx and Viatris. M.S. serves as a consultant for and/or has received research support from Lexicon, Amarin, NewAmsterdam Pharma, Silence, Sanofi, Regeneron and Tourmaline; and receives salary support from CPC, a nonprofit academic research organization affiliated with the University of Colorado, which receives or has received research grant/consulting funding between July 2021 and July 2024 from Abbott Laboratories, Agios Pharmaceuticals, Inc., Alexion Pharma Godo Kaisha, Amgen Inc., Anthos Therapeutics, Inc., ARCA biopharma, Inc., Arrowhead Pharmaceuticals, AstraZeneca Pharma India, AstraZeneca UK Ltd, Bayer, Bayer Aktiengesellschaft, Bayer Pharma AG, Beth Israel Deaconess Medical Center, Better Therapeutics, Boston Clinical Research Institute LLC, Bristol Myers Squibb, Cleerly, Inc., Colorado Dept. of Public Health and Environment, Congress Inc., Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EPG Communication Holdings Ltd., Esperion Therapeutics, Inc., Faraday Pharmaceuticals, Inc., HeartFlow Inc., Insmed, Ionis Pharmaceuticals, IQVIA Inc., Janssen Pharmaceuticals, Inc., Janssen Research & Development, LLC, Janssen Scientific Affairs LLC, Lexicon Pharmaceuticals, Inc., Medpace, Inc., Medscape, Merck Sharp & Dohme Corp., Nectero Medical, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Pfizer, PPD Development, L.P., Prothena Biosciences Limited, Regeneron, Regents of the University of Colorado (aka UCD), Sanifit Therapeutics S.A., Sanofi, Silence Therapeutics PLC, Stanford University, Stealth BioTherapeutics Inc., The Brigham and Women’s Hospital, Thrombosis Research Institute, Tourmaline Bio, Inc., University of Colorado, University of Colorado Denver, University of Pittsburgh, VarmX, Verve Therapeutics and WraSer, LLC. V.B. is an employee of Medpace. M.D., J.J.P.K., E.W., A.L.N., D.K., A.H. and M.H.D. are employees of NewAmsterdam Pharma and hold stocks or options. J.B. declares no competing interests.
